Details for Patent: 11,834,441

Which drugs does patent 11,834,441 protect, and when does it expire?

Patent 11,834,441 protects JOURNAVX and is included in one NDA.

This patent has forty patent family members in thirty-five countries.

Summary for Patent: 11,834,441

Title:	Substituted tetrahydrofurans as modulators of sodium channels
Abstract:	Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
Inventor(s):	Steven John Durrant, Nadia Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher WRAY
Assignee:	Vertex Pharmaceuticals Inc
Application Number:	US17/112,156
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,834,441

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	JOURNAVX	suzetrigine	TABLET;ORAL	219209-001	Jan 30, 2025		RX	Yes	Yes			Y	Y		TREATMENT OF MODERATE TO SEVERE ACUTE PAIN IN ADULTS USING SUZETRIGINE

International Family Members for US Patent 11,834,441

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	120680
Australia	2020397059
Brazil	112022010924